Journal
CELLULAR IMMUNOLOGY
Volume 281, Issue 1, Pages 62-67Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.cellimm.2013.01.001
Keywords
Prostaglandin E-2; IDO; Dendritic cell; Cancer vaccine; Tumor-induced immunosuppression
Categories
Funding
- Max-Eder junior Research Group Program of the Deutsche Krebshilfe
- Else Kroner-Fresenius-Stiftung [P68/08//A50/08]
Ask authors/readers for more resources
Prostaglandin E-2 has been shown to enhance the maturation, migration, and antigen-presenting capacity of DCs. It is therefore included in many maturation cocktails for the generation of monocyte-derived DCs. Paradoxically, PGE(2) is also an important tumor-derived immunosuppressive factor and has inhibitory effects on DC differentiation and function. To further investigate these seemingly contradictory results we studied whether the DC:T cell ratio has an impact on the outcome of the interaction between PGE(2)-treated DCs and T cells. Surprisingly, at high DC:T cell ratios T cell proliferation was inhibited while at low ratios PGE(2)-treated DCs displayed enhanced T cell-stimulatory properties. The inhibitory function of PGE(2)-treated DCs depended primarily on the PGE(2)-induced induction of indoleamine 2,3-dioxygenase competence. In summary, we show that PGE(2)-treated DCs can have either an immunogenic or tolerogenic function depending on the DC:T cell ratio. This finding could explain the conflicting results regarding the influence of PGE(2) on DC function. (c) 2013 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available